Your browser doesn't support javascript.
loading
HCRP1 regulates proliferation, invasion, and drug resistance via EGFR signaling in prostate cancer.
Sun, Liang; Lü, Jiaju; Ding, Sentai; Bi, Dongbin; Ding, Kejia; Niu, Zhihong; Liu, Ping.
Affiliation
  • Sun L; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China.
  • Lü J; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China.
  • Ding S; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China.
  • Bi D; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China.
  • Ding K; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China.
  • Niu Z; Department of Urology, Shandong Provincial Hospital Affiliated to Shandong University, Jinan, Shandong, 250021, China.
  • Liu P; Department of Pharmacy, Shandong Provincial Hospital Afliated to Shandong University, Jinan, Shandong, 250021, China. Electronic address: liupingmedicine@163.com.
Biomed Pharmacother ; 91: 202-207, 2017 Jul.
Article de En | MEDLINE | ID: mdl-28458158
ABSTRACT
Previous studies showed that HCRP1 is decreased in tumor cells compared with normal tissue, and functions as a tumor suppressor. However, its expression pattern and function in human prostate cancer remain unclear. In this study we examined HCRP1 expression in prostate cancer cell lines via western blotting. Thereafter, we performed CCK-8 assay and matrigel invasion assay after cells were transfected with HCRP1 overexpression plasmid or siRNA. We further investigated the possible mechanism involved in HCRP1's regulation to prostate cancer cell proliferation and invasion. We found that HCRP1 negatively regulates EGFR activity and expression of its downstream proteins. Moreover, we found that HCRP1 is negatively correlated with multi-drug resistant related proteins after cells were treated with paclitaxel, cisplatin or gefitinib, indicating its inhibiting effect of chemotherapy resistance. In summary, our results provided evidence that HCRP1 is a negative regulator in prostate cancer progression, metastasis and multi-drug resistance.
Sujet(s)
Mots clés

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la prostate / Transduction du signal / Complexes de tri endosomique requis pour le transport / Récepteurs ErbB Type d'étude: Prognostic_studies Limites: Humans / Male Langue: En Journal: Biomed Pharmacother Année: 2017 Type de document: Article Pays d'affiliation: Chine

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de la prostate / Transduction du signal / Complexes de tri endosomique requis pour le transport / Récepteurs ErbB Type d'étude: Prognostic_studies Limites: Humans / Male Langue: En Journal: Biomed Pharmacother Année: 2017 Type de document: Article Pays d'affiliation: Chine